shelf(0)

No. 056 · Combos · Peptide Blend

DSIP + Selank

— Not ranked · combination how tiers work →
  • Not approved as a combo
  • WADA — not listed
Compare Cite
Fingerprint combination
DSIP + Selank (no defined sequence)

Combos are blends of separate compounds, so there is no single sequence. This ring motif is decorative — open a component for its fingerprint.

01

Quick answers

What is DSIP + Selank?
A sleep-and-calm blend pairing the delta-sleep inducer DSIP with the anxiolytic Selank to promote deep sleep onset while reducing evening anxiety and racing thoughts. Delta sleep-inducing peptide (DSIP) plus Selank.
What is in DSIP + Selank?
DSIP + Selank typically combines DSIP and Selank. Commercial products vary.
How strong is the evidence for DSIP + Selank?
It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. DSIP has small human sleep studies, including a double-blind trial in chronic insomnia; Selank has Russian clinical studies.
Is DSIP + Selank FDA-approved?
No. DSIP + Selank is not an approved product; no regulator has reviewed the combination.
Is DSIP + Selank banned in sport?
No. DSIP + Selank is not on the World Anti-Doping Agency Prohibited List.
How does DSIP + Selank work?
This blend targets complementary sleep and anxiety pathways: DSIP modulates GABAergic/glutamatergic neurotransmission to promote delta-wave deep sleep and normalizes the cortisol/ACTH circadian rhythm, while Selank potentiates GABA-A receptor activity and modulates serotonin to reduce pre-sleep anxiety without sedative hangover effects.
What is known about the safety of DSIP + Selank?
Both components have been studied in human settings. DSIP is an endogenous peptide with a favorable safety profile.

Last reviewed · editorial policy · markdown

02

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

Not ranked: combinations have no published studies of their own. See the components below.

A PubMed search found no published studies of this combination; only reviews mention it. DSIP has small human sleep studies, including a double-blind trial in chronic insomnia; Selank has Russian clinical studies.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

03

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved as a combination
WADA
Not on the Prohibited List
04

Overview

A sleep-and-calm blend pairing the delta-sleep inducer DSIP with the anxiolytic Selank to promote deep sleep onset while reducing evening anxiety and racing thoughts.

Research status No published studies of the combination; DSIP has small human sleep studies and Selank has Russian clinical studies

05

Mechanism

This blend targets complementary sleep and anxiety pathways: DSIP modulates GABAergic/glutamatergic neurotransmission to promote delta-wave deep sleep and normalizes the cortisol/ACTH circadian rhythm, while Selank potentiates GABA-A receptor activity and modulates serotonin to reduce pre-sleep anxiety without sedative hangover effects.

06

Effects reported in research

These outcomes are attributed to the individual components. The combination itself has not been studied.

  • Promoted deep restful sleep
  • Reduced pre-sleep anxiety
  • Improved sleep continuity and duration
  • Morning-after calm without grogginess
07

Safety & unknowns

Both components have been studied in human settings. DSIP is an endogenous peptide with a favorable safety profile. Selank is approved in Russia without sedation or dependency risks. No combination-specific safety data. Expected to be well-tolerated. Not FDA-approved.

Unknowns. The combination itself has not been studied; interactions between its components are unknown.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [2]

  1. Clinical trial 2008

    [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]

    Zozulia AA, Neznamov GG, Siuniakov TS, et al. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

    Comparative trial of the Selank component versus medazepam in 62 patients with generalized anxiety disorder or neurasthenia, reporting similar anxiolytic effects.

    [pubmed]

  2. Review 1984

    Delta-sleep-inducing peptide (DSIP): a review

    Graf MV, Kastin AJ. Neuroscience and Biobehavioral Reviews

    Review of the DSIP component covering its distribution in brain and plasma and reported effects on sleep, electrophysiology, hormones, and circadian patterns.

    [pubmed] [doi]

09

Components

DSIP Tier A · Controlled human trials A Selank Tier A · Controlled human trials A
11

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

12

Cite this entry

$ cite --format=apa

peptidemeta. (2026). DSIP + Selank. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/dsip-selank/

$ cite --format=bibtex 
@misc{peptidemeta-dsip-selank,
  title = {DSIP + Selank},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/dsip-selank/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open